Stock Details

Enter Company or Symbol. Press down arrow for suggestions, or Escape to return to entry field.

RELATED RESOURCES

Change Text Size:

BRIEF-AnPac Bio Class III Medical Device Passes Extensive NMPA Registration Tests

BY Reuters
— 7:42 AM ET 01/04/2022

Jan 4 (Reuters) - AnPac Bio-Medical Science Co Ltd (ANPC):

* ANPAC BIO CLASS III MEDICAL DEVICE PASSES EXTENSIVE NMPA REGISTRATION TESTS AND WILL START CLINICAL TRIAL IN Q1, 2022 Source text for Eikon: Further company coverage:

Copyright © Reuters 2008. All rights reserved. Republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters and the Reuters sphere logo are registered trademarks and trademarks of the Reuters group of companies around the world.

More ANPC News

AnPac Bio Class III Medical Device Passes Extensive NMPA Registration Tests and Will Start Clinical Trial in Q1, 2022
GlobeNewswire - 7:30 AM ET 01/04/2022
Technical Paper on AnPac Bio Novel CDA Cancer Detection Technology Published by Peer-Reviewed International Medical Journal
GlobeNewswire - 7:30 AM ET 12/10/2021
AnPac Bio Reports Nine Months Ended September 30, 2021, Same Period Achieved Record Revenue Increased By 55.3% While Non-GAAP Net Loss Reduced by 6.8%
GlobeNewswire - 1:30 PM ET 11/26/2021